Psychosis clinical trials

Explore recruiting psychosis clinical trials.

Recruiting psychosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Psychosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis

Spain, Bulgaria, France, Italy, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

CN0120056: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-4)

Bulgaria, Croatia, Romania, Germany, Belgium, France +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Master Protocol for Three, Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled, Efficacy and Safety Studies of ACP-204 in Adults with Alzheimer's Disease Psychosis

Czechia, France, Bulgaria, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficiency of a composite personalised care on functional outcome in early psychosis: A Prospective Randomised Controlled Trial

France

Therapeutic use (Phase IV) EU CTIS Study details

EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Psychosis trials by city

Psychosis in Toronto Psychosis in Vancouver Psychosis in Montreal Psychosis in Calgary Psychosis in Edmonton Psychosis in Ottawa Psychosis in Winnipeg Psychosis in Quebec City Psychosis in Hamilton Psychosis in Kitchener Psychosis in London Psychosis in Halifax Psychosis in New York Psychosis in Los Angeles Psychosis in Chicago Psychosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease